The U.S. Food and Drug Administration (FDA) has cleared the Flow FL-100, marking a significant advancement in at-home depression treatment. This innovative device utilizes gentle electrical stimulation to target brain regions associated with mood regulation, offering a new prescription-only option for adults grappling with major depression. It stands as the first at-home brain-stimulation device to receive FDA clearance for this specific indication.

Developed by Flow Neuroscience, the FL-100 is slated for release in the United States in spring 2026. The device has already established its presence in several international markets, including Europe, the United Kingdom, Switzerland, and Hong Kong. Its introduction reflects the ongoing scientific pursuit of diverse and effective treatments for depression, particularly for individuals who find traditional medications or talk therapy insufficient.

The FL-100 operates through transcranial direct current stimulation (tDCS), a non-invasive technique that delivers a low-intensity direct current ranging from 0.5 to 2 milliamperes. Administered via two electrodes placed on the scalp, this current is significantly weaker than that used in electroconvulsive therapy (ECT), which typically involves about 800 milliamperes and is strong enough to induce seizures. The aim is to restore healthy activity in the prefrontal cortex, a brain area often underactive in depressed individuals.

FDA clearance followed a rigorous evaluation of a randomized, placebo-controlled clinical trial published in Nature Medicine. The study involved 174 adults diagnosed with at least moderate depression, who were assigned to either an “active” tDCS group or an “inactive” (placebo) group. Participants underwent a 10-week treatment regimen, commencing with five 30-minute sessions weekly for three weeks, followed by three weekly sessions for the subsequent seven weeks.

The trial yielded compelling results, demonstrating substantially higher rates of treatment response and remission in the active tDCS group. A notable 45 percent of individuals utilizing the FL-100 achieved remission from their depressive symptoms, a figure nearly double the 22 percent observed in the control group. Improvements were comprehensively noted across various symptoms, including mood, energy levels, sleep quality, concentration, and anxiety.

Dr. Samuel Wilkinson, an associate professor of psychiatry at Yale Medicine, who was not involved in the device’s development, described the FL-100 as “another arrow in the quiver.” Daniel Mansson, chief science officer and co-founder of Flow Neuroscience, highlighted the device’s ability to show rapid clinical results, often within three to four weeks. He also emphasized its external targeting of the brain, which bypasses the systemic side effects, such as weight gain or sexual dysfunction, commonly associated with oral antidepressant medications.

The device generally presents minimal side effects, primarily localized tingling at the electrode sites, brief skin irritation, or mild headaches. Instances of skin burns have been rare, occurring predominantly when users disregarded instructions, such as reusing electrodes or allowing electrode pads to dry out. This safety profile makes it an appealing alternative for patients seeking to mitigate the adverse effects often linked with pharmacological treatments.

While the precise neurological mechanisms remain subjects of ongoing research, theories suggest the FL-100 works by normalizing activity in the prefrontal cortex, a region critical for mood regulation that often exhibits reduced activity in individuals with depression. Dr. Kultar Garcha, Flow’s chief medical officer, underscored the device’s safety and remarkable convenience. He noted that the wireless headset allows users to administer treatment at home for just 30 minutes, seamlessly integrating into daily routines without disruption.

The FL-100 appears particularly well-suited for patients earlier in their depression treatment journey, rather than as a last resort. Dr. Garcha suggested it could be highly effective when a patient’s brain is “primed for plasticity,” making it adaptable to relearn healthy patterns following a recent change in their condition or life circumstances. It also offers a viable option for those wishing to avoid medication entirely or individuals already on antidepressants who require an additional therapeutic boost.

Flow Neuroscience anticipates the FL-100’s U.S. retail price will range between $500 and $800, though specific pricing for electrode pads or potential subscription components has not yet been released. The company is actively engaging with U.S. insurance payers to explore various coverage pathways, aiming for broad reimbursement through commercial and other insurance plans. However, widespread coverage is unlikely to be in place at the device’s Q2 2026 launch.

Read Original

Keywords: Flow FL-100, depression treatment, at-home brain stimulation, FDA clearance, transcranial direct current stimulation (tDCS), major depressive disorder, non-invasive depression therapy, Flow Neuroscience